文献速递类风湿关节炎

JAK抑制对类风湿关节炎骨骼肌的影响:RAMUS单臂实验医学研究

Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study.
PubMed 文献 · Lancet Rheumatol · 2025-10-15

RAMUS是一项在英国Freeman医院开展的前瞻性、单臂、单中心、概念验证实验研究,纳入15例启动托法替布标准治疗的类风湿关节炎患者。治疗6个月后下肢肌肉体积平均增加242 cm³(95%CI 44-441,p=0.017),血清肌酐显著升高(p=0.0011),而四肢瘦体重指数、肌力与肌肉功能无显著变化。作者认为血清肌酐升高可能反映肌肉体积增加,需更大规模研究验证。

要点

  • 托法替布治疗6个月后下肢肌肉体积显著增加,尤以大腿为著。
  • 血清肌酐显著升高,但四肢瘦体重指数、肌力与肌肉功能无显著变化。
  • 15例中13例(87%)记录到不良事件,1例为严重不良事件(启动托法替布前因COVID-19肺炎住院)。

核心结论

  • 托法替布治疗类风湿关节炎患者6个月后与下肢肌肉体积增加相关。
  • 托法替布相关的血清肌酐升高可能反映肌肉体积增加,机制可能为对骨骼肌的直接药理作用或炎症减轻,或两者兼有。
  • 作者认为需要更大规模研究来验证本研究发现、证明功能获益,并确定这些效应是否为托法替布所独有。

研究设计与样本

  • RAMUS为前瞻性、单臂、单中心、概念验证实验研究,在英国纽卡斯尔Freeman医院开展。
  • 纳入年龄大于18岁、按2010年ACR-EULAR分类标准诊断类风湿关节炎并启动托法替布标准治疗的患者。
  • 附加纳入标准为至少一项肌少症危险因素、既往未接受JAK抑制剂治疗、基线访视前至少4周未接受全身糖皮质激素治疗、血清肌酐不超过正常上限1.5倍。
  • 2021年1月21日至2023年3月1日筛查22例,15例(68%)符合条件并完成研究;15例中女性13例(87%)、男性2例(13%),白人12例(80%),平均年龄59.6岁(SD 10.0)。
  • 主要结局为基线、治疗1个月和6个月时定量MRI评估的下肢肌肉体积变化,在所有完成研究的参与者中评估。

主要发现

  • 托法替布治疗6个月后下肢肌肉体积显著增加,平均增加242 cm³(95%CI 44-441,p=0.017),尤以大腿为著。
  • 托法替布治疗6个月后血清肌酐显著升高(p=0.0011)。
  • 托法替布治疗1个月后DAS28-CRP显著降低(p=0.0064),6个月时无进一步变化。
  • 四肢瘦体重指数、肌力与肌肉功能均未观察到显著变化。
  • 15例参与者中13例(87%)记录到28起不良事件,其中1起为严重不良事件,涉及一名参与者在开始托法替布前因COVID-19肺炎住院。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要更大规模研究来验证本研究发现、证明功能获益,并确定这些效应是否为托法替布所独有。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis increases the risk of generalised muscle wasting, with chronic inflammation contributing to the loss of muscle mass and strength. Tofacitinib, a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, increases serum creatinine concentrations without conclusive evidence of nephrotoxicity. In the Rheumatoid Arthritis and Muscle (RAMUS) study, we investigated whether tofacitinib affects muscle volume, strength, and function. METHODS: RAMUS was a prospective, single-arm, single-centre, proof of concept experimental study, done at Freeman Hospital, Newcastle upon Tyne, UK. Patients aged older than 18 years, with rheumatoid arthritis (according to the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology [ACR-EULAR] classification criteria for rheumatoid arthritis) initiating tofacitinib as standard care were recruited. Additional inclusion criteria were at least one sarcopenia risk factor, no previous treatment with JAK inhibitors, no systemic glucocorticoid treatment for at least 4 weeks before the baseline visit, and serum creatinine 1·5 times the upper limit of normal or less. Participants provided blood samples at baseline, 1 month, and 6 months; vastus lateralis biopsies were performed at baseline and 6 months. The primary outcome was change in lower limb muscle volume, assessed by quantitative MRI at baseline and after 1 and 6 months of tofacitinib treatment, and was assessed in all participants who completed the study. Secondary outcomes included changes in serum creatinine, appendicular lean mass index, muscle strength, muscle function, and disease activity (Disease Activity Score 28-C-reactive Protein [DAS28-CRP] score). Adverse events were recorded. People with lived experience with rheumatoid arthritis were involved in the design and set-up phases of this study. RAMUS was registered with ISRCTN (ISRCTN13364395). FINDINGS: Between Jan 21, 2021, and March 1, 2023, 22 patients were screened, and 15 (68%) were eligible and completed the study. 13 (87%) of 15 patients were female, two (13%) were male, 12 (80%) were White, and the mean age was 59·6 years (SD 10·0). After 6 months, tofacitinib treatment was associated with significant increases in lower limb muscle volume (mean increase 242 cm3 [95% CI 44-441], p=0·017), particularly in the thigh, and significant increases in serum creatinine (p=0·0011). Disease activity (DAS28-CRP) was significantly reduced after 1 month of tofacitinib treatment (p=0·0064) with no further changes at 6 months. No significant changes in appendicular lean mass index, muscle strength, or muscle function were observed. 28 adverse events were recorded in 13 (87%) of 15 participants; one event was classified as severe and serious, and concerned a participant being hospitalised with COVID-19 pneumonitis before commencing tofacitinib. INTERPRETATION: Tofacitinib treatment in patients with rheumatoid arthritis was associated with increased muscle volume after 6 months. The increase in serum creatinine associated with tofacitinib treatment might reflect increased muscle volume via a direct pharmacological effect on skeletal muscle or via reduced inflammation, or a combination. Larger studies are needed to verify our findings, demonstrate functional benefit, and determine whether they are unique to tofacitinib. FUNDING: Pfizer, BMA Foundation, JGW Patterson Foundation and Newcastle Hospitals Charity.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bennett JL, Hollingsworth KG, Pratt AG, et al. Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study. Lancet Rheumatol. 2025. PMID: 41109315. doi:10.1016/S2665-9913(25)00184-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。